Skip to Main Content

Multiple myeloma patients treated with an experimental CAR-T therapy developed by Bluebird Bio and licensed to Celgene went nearly one year before their cancer progressed, according to updated study results presented Friday night at the annual meeting of the American Society of Clinical Oncology.

The durability of responses to Bluebird’s CAR-T, called BB2121, is a focal point for investors at this year’s ASCO meeting. The exact number — median progression-free survival of 11.8 months — effectively meets the lower end of expectations, which ranged as high as 15 months, based on analyst reports.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Prolong a dying mothers life by a year
    Adam bashes.
    This vile blogger is a disgrace and karma will not
    Be kind.

    Hopefully one day someone in his family needs a drug to live ONE YEAR MORE

    and that company tells the basher Adam F U

Comments are closed.